Published in Lancet on March 27, 2010
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med (2013) 2.47
Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One (2011) 2.05
Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ (2011) 1.61
Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial. PLoS Med (2016) 1.49
A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med (2014) 1.36
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One (2012) 1.33
Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One (2013) 1.29
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc (2012) 1.21
Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis (2014) 1.11
A reduction in adult blood stream infection and case fatality at a large African hospital following antiretroviral therapy roll-out. PLoS One (2014) 1.08
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis (2012) 1.07
Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique. Malar J (2012) 1.00
How operational research influenced the scale up of antiretroviral therapy in Malawi. Health Care Manag Sci (2011) 0.95
Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional hospital, Cameroon. BMC Res Notes (2013) 0.95
The impact of home-based HIV counseling and testing on care-seeking and incidence of common infectious disease syndromes in rural western Kenya. BMC Infect Dis (2014) 0.92
Operational research in Malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV. BMC Public Health (2011) 0.92
Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. PLoS One (2012) 0.92
Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc (2012) 0.90
Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study. AIDS (2016) 0.86
The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa. Future Virol (2012) 0.84
Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy. Bull World Health Organ (2011) 0.84
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother (2014) 0.83
Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program. PLoS One (2014) 0.83
Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bull World Health Organ (2015) 0.83
Self-care practices and experiences of people living with HIV not receiving antiretroviral therapy in an urban community of Lusaka, Zambia: implications for HIV treatment programmes. AIDS Res Ther (2013) 0.83
Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health (2015) 0.83
Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS One (2014) 0.82
Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. J Acquir Immune Defic Syndr (2015) 0.81
HIV-Associated Tuberculosis. Clin Dev Immunol (2010) 0.81
Weight as predictors of clinical progression and treatment failure: results from the TREAT Asia Pediatric HIV Observational Database. J Acquir Immune Defic Syndr (2014) 0.81
Co-trimoxazole, cART, and non-AIDS infectious diseases. Lancet (2010) 0.79
Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis (2011) 0.78
Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial. Trials (2015) 0.78
Evident stabilization of the clinical profile in HIV/AIDS as evaluated in an open label clinical trial using a polyherbal formulation. Indian J Med Res (2013) 0.77
Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Malar J (2016) 0.76
Trends in prevalence of diarrhoea, Kaposi's sarcoma, bacterial pneumonia, malaria and geohelminths among HIV positive individuals in Uganda. AIDS Res Ther (2015) 0.76
Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis. Afr Health Sci (2015) 0.76
Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study. Malar J (2016) 0.75
Improved health among people living with HIV/AIDS who received packages of proven preventive health interventions, Amhara, Ethiopia. PLoS One (2014) 0.75
Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch Hospital, Ethiopia. Ther Clin Risk Manag (2017) 0.75
Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods. PLoS One (2011) 0.75
Improved survival with co-trimoxazole prophylaxis among people living with HIV/AIDS who initiated antiretroviral treatment in Henan Province, China. Curr HIV Res (2014) 0.75
Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. J Acquir Immune Defic Syndr (2015) 0.75
The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models. Am J Epidemiol (2015) 0.75
Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis. J Infect Dis (2016) 0.75
Trends and Predictors of Mortality Among HIV Positive Patients in the Era of Highly Active Antiretroviral Therapy in Uganda. Infect Dis Rep (2015) 0.75
Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda. J Acquir Immune Defic Syndr (2016) 0.75
Frequent malaria illness episodes in two Malawian patients on antiretroviral therapy soon after stopping cotrimoxazole preventive therapy. Malawi Med J (2017) 0.75
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet (1999) 6.40
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS (2006) 5.87
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet (2004) 4.25
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet (2004) 4.19
Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr (2007) 3.71
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med (1992) 2.65
Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS (2008) 2.05
Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med (1994) 1.92
Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS (2005) 1.88
Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother (2009) 1.84
Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ (1999) 1.81
Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet (1991) 1.72
Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS (2001) 1.64
Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS (2007) 1.41
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med (2001) 1.27
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med (2001) 1.23
Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.10
CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom (2008) 1.03
Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. AIDS (2003) 1.02
Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med (1991) 12.89
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1993) 11.01
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (1994) 8.73
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med (1997) 8.43
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet (1995) 4.31
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet (2004) 4.25
23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Changes in annual tuberculosis notification rates between 1978/79 and 1983 for the population of Indian subcontinent ethnic origin resident in England. J Epidemiol Community Health (1986) 3.48
Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet (1998) 3.22
Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology (2007) 3.14
Evaluation of microscope condition in Malawi. Trans R Soc Trop Med Hyg (2000) 3.03
Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax (2001) 3.01
Health of the public. The academic response. Health of the Public Mission Statement Working Group. JAMA (1992) 2.95
Tuberculosis: old reasons for a new increase? BMJ (1995) 2.92
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet (1986) 2.88
The operation, quality and costs of a district hospital laboratory service in Malawi. Trans R Soc Trop Med Hyg (2004) 2.84
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet (1997) 2.77
Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest (1984) 2.71
The epidemiology of HIV-1 infection in urban areas, roadside settlements and rural villages in Mwanza Region, Tanzania. AIDS (1992) 2.70
Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ (1999) 2.68
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Changes in tuberculosis notification rates in the white ethnic group in England and Wales between 1953 and 1983. J Epidemiol Community Health (1988) 2.67
Rolling out antiretrovirals in Africa: there are still challenges ahead. Clin Infect Dis (2005) 2.43
Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS (2001) 2.41
Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis (1999) 2.37
Appropriate treatment of malaria? Use of antimalarial drugs for children's fevers in district medical units, drug shops and homes in eastern Uganda. Trop Med Int Health (2002) 2.35
Community engagement in health research: two decades of experience from a research project on HIV in rural Uganda. Trop Med Int Health (2009) 2.33
Undetected eye disease in a primary care clinic population. Arch Intern Med (1994) 2.32
Derivation of mouse intestinal crypts from single progenitor cells. Nature (1985) 2.31
Risk assessment and other screening options for gonorrhoea and chlamydial infections in women attending rural Tanzanian antenatal clinics. Bull World Health Organ (1995) 2.29
Can health visitors prevent fractures in elderly people? BMJ (1992) 2.25
Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care (2000) 2.23
Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J Clin Microbiol (1993) 2.20
Predicting survival in malignant mesothelioma. Eur Respir J (2011) 2.15
Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania. Sex Transm Infect (2003) 2.14
PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med (2004) 2.10
The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res (1993) 2.05
Sexual behaviour patterns and other risk factors for HIV infection in rural Tanzania: a case-control study. AIDS (1997) 2.05
Tuberculosis and HIV: estimates of the overlap in England and Wales. Thorax (1993) 2.04
Issues in data monitoring and interim analysis of trials. Health Technol Assess (2005) 1.96
Clonal relationships among bloodstream isolates of Escherichia coli. Infect Immun (1995) 1.95
Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis (2005) 1.95
Bone and joint tuberculosis. A survey of notifications in England and Wales. J Bone Joint Surg Br (1984) 1.93
Genetics of coeliac disease. QJM (1996) 1.90
Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS (1998) 1.89
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer (1989) 1.88
Community action for health promotion: a review of methods and outcomes 1990-1995. Am J Prev Med (1997) 1.86
Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proc Natl Acad Sci U S A (1996) 1.86
A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis (1995) 1.85
The impact of physiological noise correction on fMRI at 7 T. Neuroimage (2011) 1.82
Research needs for an improved primary care response to chronic non-communicable diseases in Africa. Trop Med Int Health (2009) 1.79
Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax (1989) 1.75
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS (1997) 1.73
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet (1994) 1.71
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 1.68
Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol (2001) 1.67
Randomised trials of STD treatment for HIV prevention: report of an international workshop. HIV/STD Trials Workshop Group. Genitourin Med (1997) 1.66
Filters on the pathway to mental health care, II. Sociodemographic factors. Psychol Med (1995) 1.66
Trends in bloodstream infections among human immunodeficiency virus-infected adults admitted to a hospital in Nairobi, Kenya, during the last decade. Clin Infect Dis (2001) 1.66
Admission trends in a rural South African hospital during the early years of the HIV epidemic. JAMA (1999) 1.65
Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood (1997) 1.64
Protein kinase C zeta phosphorylates a subset of selective sites of the NADPH oxidase component p47phox and participates in formyl peptide-mediated neutrophil respiratory burst. J Immunol (2001) 1.64
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (1992) 1.63
Rationale and design of the MEMA kwa Vijana adolescent sexual and reproductive health intervention in Mwanza Region, Tanzania. AIDS Care (2006) 1.62